LONDON – These are hardly times for a fanfare, but this month saw the unveiling of a new name in bioprocessing, following the formal closing of the $21.4 billion sale of GE Healthcare’s Life Sciences to Danaher Corp. The business, now renamed Cytiva, has turnover of $3.3 billion, nearly 7,000 employees and operations in 40 countries. More than 75% of FDA-approved biologic drugs use its products in their manufacture.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Apollo Endosurgery, Atricure, Eos imaging, Kolon Tissuegene, Piranha Medical, Pluristem, Predictive Biotech, Predictive Technology, Rethink My Health, Scworx, Shockwave Medical, Staar Surgical.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allen Technologies, Alphatec Holdings, Auburn University, Avacta Group, Biobot Analytics, Biodesix, Chembio Diagnostics, Cryo Innovations, Cytiva, Genomoncology, Hai Kang, HPC-AI, Integra Lifesciences, Intuitive, JMA, Labcorp, Myomo, Myriad, Nanomix, National Supercomputing Centre, Novacyt Group, Organovo, Pacific Biosciences of California, Pharmacyte, Phunware, Ping An Good Doctor, Predictive Laboratories, Resolution Medical, Roji Health Intelligence, Tarveda Therapeutics, Vitalhub, Wellgistics.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Arch, Arcturus, Ascletis, Astrazeneca, Athersys, Beigene, Can-Fite, Fennec, Hope, Merck, Predictive Biotech, Proteostasis, Ridgeback.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 89bio, Alimera, Cannabics, Celltrion, CNS, Coherus, Connectyx, Enlivex, Fulcrum, Gilead, La Jolla, Medgenome, Ocular, Orgenesis, Pluristem, Redhill, Tamir, Thermogenesis, Vaxil, WPD.